Acute and chronic phase platelet aggregability studies in Chinese patients after implantation of a permanent transvenous pacemaker.
It has been suggested that the incidence of thromboembolic events always increases in patients after insertion of a transvenous pacemaker. Blood samples from twenty consecutive patients (fifteen males and five females) before and after pacemaker implantation was retained for platelet aggregability studies which were analyzed separately with ADP, collagen, epinephrine and arachidonic acid. The maximal amplitude of platelet aggregatory curve was detected by an aggregometer. The samples collected the day before pacemaker implantation (day 0) were used as self-control. Day 1 and day 3 after pacemaker implantation were defined as the acute phase, while day 30 was defined as the chronic phase. The maximal amplitude of platelet aggregatory curve was observed to be lowest on day 1 and then return to normal on day 3 and day 30. The results of platelet aggregability, however, showed no significant difference (P>0.05) between self-control and post-implantation samples. In conclusion, there was no significant change in platelet aggregability for either acute or chronic phases after pacemaker implantation. Antiplatelet medications may not be necessary for the prevention of thromboembolic events after the implantation of a pacemaker.
Kong
C W
CW
Division of Cardiology, Veterans General Hospital, Taipei, Taiwan. ROC.
Shih
C J
CJ
Hsiao
H C
HC
Chang
H Y
HY
Tai
H C
HC
Lee
K H
KH
Hu
H Y
HY
Tzeng
C H
CH
D000368:Aged; D002681:China; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial / Q000009:adverse effects*; D010974:Platelet Aggregation / Q000502:physiology*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010979:Platelet Function Tests; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control
D010975:Platelet Aggregation Inhibitors